| Identification | Back Directory | [Name]
Fevipiprant | [CAS]
872365-14-5 | [Synonyms]
QAW039
CS-2449
Fevipipran
NVP-QAW039
Fevipiprant
NVP-QAW039;QAW039
Fevipiprant (QAW039)
Fevipiprant(NVP-QAW039)
NVP-QAW039; QAW039;QAW039;QAW-039;QAW 039;FEVIPIPRANT
NVP-QAW039; NVP-QAW 039; NVP-QAW-039 QAW-039; QAW039; QAW 039; FEVIPIPRANT
2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid
1H-Pyrrolo[2,3-b]pyridine-3-acetic acid, 2-methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]- | [Molecular Formula]
C19H17F3N2O4S | [MDL Number]
MFCD22548206 | [MOL File]
872365-14-5.mol | [Molecular Weight]
426.41 |
| Chemical Properties | Back Directory | [Boiling point ]
637.6±55.0 °C(Predicted) | [density ]
1.44±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/mL; DMF:PBS(pH7.2) (1:2): 0.33 mg/mL; DMSO: 10 mg/mL; Ethanol: 1 mg/mL | [form ]
A crystalline solid | [pka]
3.33±0.30(Predicted) |
| Hazard Information | Back Directory | [Uses]
Fevipiprant is used in the oral treatment of asthma and has been successful in targeting severe eosinophilic asthma.Fevipiprant is a novel oral prostaglandin D2 receptor 2 (DP2; known as CRTh2) antagonist and currently in development for the treatment of severe asthma and atopic dermatitis. | [storage]
Store at -20°C |
|
|